Saarvienin A, a newly identified glycopeptide antibiotic from Amycolatopsis, exhibits strong activity against multidrug-resistant bacteria, including vancomycin-resistant Enterococcus and MRSA.

More information: Amninder Kaur et al, Saarvienin A—A Novel Glycopeptide with Potent Activity against Drug‐Resistant Bacteria, Angewandte Chemie International Edition (2025). DOI: 10.1002/anie ...

Glycopeptide enrichment is a prerequisite to enable structural characterization of protein glycosylation in glycoproteomics. Here the authors present an improved method for glycopeptide enrichment ...

Department of Chemistry, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208, United States ...

An international team of researchers, led by the University of Vienna and the Helmholtz Institute for Pharmaceutical Research Saarland, has discovered saarvienin A, a new type of glycopeptide ...

An international team of researchers has discovered saarvienin A, a new type of glycopeptide antibiotic. Their findings introduce a compound with strong activity against highly resistant bacterial ...

Recent Advances in Glycopeptide Hydrogels: Design, Biological Functions, and Biomedical Applications Jinpeng Zhang Jianghao Zou doi 10.3389/fbioe.2025.1577192 261 views REVIEW Published on 23 Apr 2025 ...

The star of the story is saarvienin A, a brand-new glycopeptide antibiotic produced by an unusual strain of Amycolatopsis, a genus of bacteria known for making medical heavy-hitters like vancomycin.

Ubiquitination occurs at K residues and palmitoylation at C residues, both on the C-terminus. Apart from the direct glycopeptide enrichment, capturing cell-surface proteins prior to glycopeptide ...

Researchers have synthesized a new compound called infuzide that shows activity against resistant strains of pathogens.

Bleomycins are a family of glycopeptide antibiotics with antitumour activity. They are used clinically in combination chemotherapy against lymphomas, squamous-cell carcinomas and germ-cell tumours.